JP2009524014A - 子癇前症の検出及び予測 - Google Patents

子癇前症の検出及び予測 Download PDF

Info

Publication number
JP2009524014A
JP2009524014A JP2008549934A JP2008549934A JP2009524014A JP 2009524014 A JP2009524014 A JP 2009524014A JP 2008549934 A JP2008549934 A JP 2008549934A JP 2008549934 A JP2008549934 A JP 2008549934A JP 2009524014 A JP2009524014 A JP 2009524014A
Authority
JP
Japan
Prior art keywords
stnfαr1
mmp
subject
level
determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008549934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009524014A5 (enExample
Inventor
ポストン，ルチッラ
シェナン，アンドリュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revvity Health Sciences Inc
Original Assignee
PerkinElmer Health Sciences Inc
Revvity Health Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PerkinElmer Health Sciences Inc, Revvity Health Sciences Inc filed Critical PerkinElmer Health Sciences Inc
Publication of JP2009524014A publication Critical patent/JP2009524014A/ja
Publication of JP2009524014A5 publication Critical patent/JP2009524014A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Mold Materials And Core Materials (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Holo Graphy (AREA)
JP2008549934A 2006-01-17 2007-01-17 子癇前症の検出及び予測 Pending JP2009524014A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0600916.1A GB0600916D0 (en) 2006-01-17 2006-01-17 detecting and predicting pre-eclampsia
PCT/GB2007/000123 WO2007083099A1 (en) 2006-01-17 2007-01-17 Detecting and predicting pre-eclampsia

Publications (2)

Publication Number Publication Date
JP2009524014A true JP2009524014A (ja) 2009-06-25
JP2009524014A5 JP2009524014A5 (enExample) 2010-02-25

Family

ID=35998177

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008549934A Pending JP2009524014A (ja) 2006-01-17 2007-01-17 子癇前症の検出及び予測

Country Status (10)

Country Link
US (1) US7638287B2 (enExample)
EP (1) EP1974220B1 (enExample)
JP (1) JP2009524014A (enExample)
AT (1) ATE504002T1 (enExample)
AU (1) AU2007206756B2 (enExample)
CA (1) CA2602681C (enExample)
DE (1) DE602007013524D1 (enExample)
ES (1) ES2364314T3 (enExample)
GB (1) GB0600916D0 (enExample)
WO (1) WO2007083099A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522634A (ja) * 2010-03-24 2013-06-13 プリールミナ ダイアグノスティックス エービー 子癇前症の初期段階マーカーとしてのＨｂＦおよびＡ１Ｍ
JP2015519107A (ja) * 2012-04-24 2015-07-09 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． 子癇前症スクリーニング方法
JP2018519819A (ja) * 2015-06-22 2018-07-26 セントレ オスピタリエ ユニヴェルシテール ド ルーアン 胎児性アルコール症候群により引き起こされる障害の診断方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008098734A1 (en) 2007-02-12 2008-08-21 Stefan Hansson Diagnosis and treatment of preeclampsia
GB0715030D0 (en) * 2007-08-02 2007-09-12 Wilson Carol J Testing process
US8647832B2 (en) 2008-01-25 2014-02-11 Perkinelmer Health Sciences, Inc. Methods for determining the risk of prenatal complications
CN102224422A (zh) * 2008-11-20 2011-10-19 珀金埃尔默健康科学公司 使用pigf-2和pigf-3标志物确定先兆子痫风险的方法
WO2010091253A1 (en) 2009-02-06 2010-08-12 Women & Infants' Hospital Of Rhode Island Compositions, formulations and methods of treating preeclampsia-type disorders of pregnancy
WO2013087887A2 (en) * 2011-12-15 2013-06-20 Pronota N.V. Biomarkers and parameters for hypertensive disorders of pregnancy
WO2014124396A1 (en) * 2013-02-08 2014-08-14 University Of Iowa Research Foundation Therapeutic strategies for the treatment of preeclampsia
US10119978B2 (en) * 2013-03-15 2018-11-06 Wallac Oy System and method for determining risk of diabetes based on biochemical marker analysis
EP3189336B1 (en) 2014-09-02 2018-11-07 Wallac OY Method for determining risk of pre-eclampsia
US20200395127A1 (en) * 2017-11-17 2020-12-17 University Of Washington Connected system for information-enhanced test results
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
GB2620035A (en) * 2021-02-10 2023-12-27 Mirvie Inc Methods and systems for conducting pregnancy-related clinical trials
FR3157091A1 (fr) * 2023-12-26 2025-06-27 Universite De Montpellier Prédiction du comportement biomécanique de la paroi artérielle à travers l’analyse temporelle du signal oscillométrique au cours de la mesure de pression

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002037120A2 (en) * 2000-11-02 2002-05-10 King's College London Diagnosis of pre-eclampsia
WO2004095032A1 (en) * 2003-04-17 2004-11-04 University College London Screen for pre-eclampsia
WO2005031364A1 (en) * 2003-09-23 2005-04-07 The General Hospital Corporation Screening for gestational disorders
JP2005128020A (ja) * 2003-10-22 2005-05-19 F Hoffmann La Roche Ag 可溶性トランスフェリンレセプター
WO2005077007A2 (en) * 2004-02-04 2005-08-25 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5331298A (en) 1996-12-23 1998-07-17 Cambridge University Technical Services Limited Diagnosis and treatment of pathological pregnancies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002037120A2 (en) * 2000-11-02 2002-05-10 King's College London Diagnosis of pre-eclampsia
WO2004095032A1 (en) * 2003-04-17 2004-11-04 University College London Screen for pre-eclampsia
WO2005031364A1 (en) * 2003-09-23 2005-04-07 The General Hospital Corporation Screening for gestational disorders
JP2005128020A (ja) * 2003-10-22 2005-05-19 F Hoffmann La Roche Ag 可溶性トランスフェリンレセプター
WO2005077007A2 (en) * 2004-02-04 2005-08-25 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522634A (ja) * 2010-03-24 2013-06-13 プリールミナ ダイアグノスティックス エービー 子癇前症の初期段階マーカーとしてのＨｂＦおよびＡ１Ｍ
JP2015519107A (ja) * 2012-04-24 2015-07-09 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． 子癇前症スクリーニング方法
JP2018519819A (ja) * 2015-06-22 2018-07-26 セントレ オスピタリエ ユニヴェルシテール ド ルーアン 胎児性アルコール症候群により引き起こされる障害の診断方法

Also Published As

Publication number Publication date
ES2364314T8 (es) 2011-09-22
CA2602681A1 (en) 2007-07-26
CA2602681C (en) 2017-03-14
AU2007206756A1 (en) 2007-07-26
US20070178530A1 (en) 2007-08-02
GB0600916D0 (en) 2006-02-22
AU2007206756B2 (en) 2011-06-16
EP1974220A1 (en) 2008-10-01
EP1974220B1 (en) 2011-03-30
WO2007083099A1 (en) 2007-07-26
US7638287B2 (en) 2009-12-29
DE602007013524D1 (de) 2011-05-12
ATE504002T1 (de) 2011-04-15
HK1119244A1 (en) 2009-02-27
ES2364314T3 (es) 2011-08-31

Similar Documents

Publication Publication Date Title
JP2009524014A (ja) 子癇前症の検出及び予測
US9250251B2 (en) Methods for determining maternal health risks
Odibo et al. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia
Schneuer et al. Angiopoietin 1 and 2 serum concentrations in first trimester of pregnancy as biomarkers of adverse pregnancy outcomes
EP2368119B1 (en) Method for determining the risk of preeclampsia using pigf-2 and pigf-3 markers
EP3189336B1 (en) Method for determining risk of pre-eclampsia
WO2015148989A1 (en) Systems and methods to identify and treat subjects at risk for obstetrical complications
Njoroge et al. The interval between births and the risk of recurrent preeclampsia among predominantly high risk women in urban tertiary care center
US11255861B2 (en) Method for determining the risk of preterm birth
Selvarajan et al. Serum soluble FMS-like tyrosine kinase-1 in ectopic pregnancy
Sebastian et al. Angiogenic factors and uterine artery Doppler in predicting preeclampsia and associated adverse outcomes in a tertiary hospital in south India
Okmen et al. The role of fetal fibronectin and plasminogen activator inhibitor 1 biomarkers in antenatal prediction of placenta accreta spectrum
WO2014055849A1 (en) Methods for diagnosing and prognosing placental dysfunction and pre-eclampsia
HK1119244B (en) Detecting and predicting pre-eclampsia
JP2025500751A (ja) 早発性子癇前症の予後についてのバイオマーカー
MS EARLY DETECTION OF HELLP SYNDROME USING BIOLOGICAL MARKERS AND DOPPLER ULTRASONOGRAPHY

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100107

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111012

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111114

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121102